Literature DB >> 17355358

Is laparoscopically assisted radical vaginal hysterectomy for cervical carcinoma safe? A case control study with follow up.

D J Morgan1, D C Hunter, G McCracken, H R McClelland, J H Price, S P Dobbs.   

Abstract

OBJECTIVE: To compare a new surgical approach, laparoscopically assisted radical vaginal hysterectomy (LARVH) with open radical hysterectomy in women with cervical cancer. Can selected women benefit from the minimally invasive approach without compromising safety (recurrence rate) and morbidity (complications)?
DESIGN: Retrospective case control study.
SETTING: A tertiary referral unit for gynaecological malignancies. POPULATION: Thirty women undergoing LARVH were included and compared with 30 women undergoing open radical surgery. The control group was matched for age, body mass index and disease stage.
METHODS: Retrospective collection of data from patient files and follow up. MAIN OUTCOME MEASURES: Recurrence rate, complication rate, hospital stay, nodal counts, blood loss, operating time.
RESULTS: Recurrence rates were equal (6.7%). There was one death, in the LARVH group. Follow up was mean 31 months in the LARVH group and 30.9 months in the open group. Blood loss as measured by mean drop in haemoglobin was greater in the open group (2.03 versus 3.01 g/dl, P = 0.02). Transfusions were given in 40% of women in the open group and 16.7% in the LARVH group. Hospital stay was significantly less in the LARVH group (5.9 versus 7.8 nights, P = 0.003). Mean operating time was longer in the LARVH group (131 versus 187 minutes P = 0.0001). Mean nodal counts did not differ significantly (17.4 in open vs 14.8 in LARVH, P > 0.05). There were seven perioperative complications in the open group and four in the LARVH group. There have been two recurrences in each group (6.67%) at mean follow up of 31 (LARVH) and 30.9 (open) months.
CONCLUSIONS: The first 30 LARVH procedures performed in this unit are comparable in terms of safety (recurrence rate and complication rate) and economic factors (shorter hospital stay mitigating longer operating time). Further development of this technique is warranted.

Entities:  

Mesh:

Year:  2007        PMID: 17355358     DOI: 10.1111/j.1471-0528.2007.01291.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  6 in total

1.  Total laparoscopic radical hysterectomy for treatment of uterine malignant tumors: analysis of short-term therapeutic efficacy.

Authors:  Yi Shen; Zehua Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-06-17

2.  Comparative evaluation of surgical stress of laparoscopically assisted vaginal radical hysterectomy and lymphadenectomy and laparotomy for early-stage cervical cancer.

Authors:  Cai-Ying Hou; Xiu-Li Li; Feng Jiang; Rong Jie Gong; Xin Yu Guo; Yuan-Qing Yao
Journal:  Oncol Lett       Date:  2011-05-13       Impact factor: 2.967

3.  Clinical Determinants of Vaginal and Abdominal Hysterectomy for Benign Conditions at the University Teaching Hospital, Yaounde-Cameroon.

Authors:  P M Tebeu; R Tayou; J S S Antaon; Y N Mawamba; V M Koh; J P Ngou-Mve-Ngou
Journal:  J West Afr Coll Surg       Date:  2022-01-05

4.  Impact of hospital care volume on clinical outcomes of laparoscopic radical hysterectomy for cervical cancer: A systematic review and meta-analysis.

Authors:  Banghyun Lee; Kidong Kim; Youngmi Park; Myong Cheol Lim; Robert E Bristow
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

5.  Evaluation of the efficacy of laparoscopic-assisted radical vaginal hysterectomy and abdominal radical hysterectomy for treating cervical cancer: a meta-analysis.

Authors:  Zhen Zeng; Jia Liu; Tao Lv; Zonghao Feng; Lei Zhang; Qinping Liao
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2021-05-14       Impact factor: 1.195

6.  Comparison of laparoscopic-assisted radical vaginal hysterectomy and abdominal radical hysterectomy in patients with early stage cervical cancer: A retrospective study.

Authors:  Sichen Zhang; Linlin Ma; Qing Wei Meng; Dan Zhou; Tuerhongayi Moyiding
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.